Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Genetic analyses of SERPINA5 in Alzheimer’s disease
Lincoln, Sarah, Baker, Matt , Tamvaka, Nikoleta, Cabrera-Rodriguez, Janisse, Helminger, Jacqueline, Hinkle, Kelly M., Duara, Ranjan , Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Rademakers, Rosa , Matchett, Billie J. , Labuzan, Sydney A. , Duara, Ranjan , Ross, Owen A. , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

No container title available | August 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-769744/v1 Get It

Abstract Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the most common cause of dementia. Our previous studies have shown that increased expression of the SERPINA5 gene is associated with hippocampal vulnerability in AD, and that the SERPINA5 protein binds to tau and co-localizes within neurofibrillary tangles. To determine if genetic variants in the SERPINA5 gene may be contributing to this phenotype, we sequenced 103 autopsy-confirmed young-onset AD cases with a positive family history of cognitive decline. We observed one individual with a rare missense variant (rs140138746) in the SERPINA5 gene, resulting in an amino acid change (p.E228Q). We screened a further 1170 neuropathologically diagnosed AD cases and identified an additional 5 carriers of this variant, resulting in an allelic frequency of 0.002141 within our AD validation cohort, which was comparable to online genomic databases. Although not significant, SERPINA5 p.E228Q variant carriers were found to be younger at age of onset and age of death than non-carriers. SERPINA5 p.E228Q variant carriers had a longer disease duration than non-carriers, which approached significance. To further elucidate possible neuropathologic contributions of the SERPINA5 p.E228Q variant, we carried out descriptive neuropathologic burden analysis on a variant carrier that was matched to a non-carrier for age, sex, disease duration, Braak tangle stage, TDP-43 positive status, and who possessed an APOE ε4 risk allele. Interestingly, SERPINA5 burden was lower in the SERPINA5 p.E228Q carrier than the non-carrier in 9 corticolimbic brain regions studied, which exaggerated the tau:SERPINA5 immunohistochemical ratio. The SERPINA5 p.E228Q carrier was observed to have more severe neuronal loss in several brain regions compared to the non-carrier. Together, we cautiously interpret these findings to suggest that the SERPINA5 p.E228Q variant may stall tangle maturity and slow AD disease progression, thus prolonging disease duration in these individuals.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Naidu, Srihari S. , Baron, Suzanne J. , Eng, Marvin H. , Sathanandam, Shyam , Zidar, David A., Feldman, Dmitriy N. , Ing, Frank F. , Latif, Faisal , Lim, Michael J. , Henry, Timothy D. , Dangas, George , Hermiller, James, Daggubati, Ramesh , Ang, Lawrence , Box, Lyndon C., Caputo, Ronald , Cohen, Mauricio G. , Coylewright, Megan , Duffy, Peter L. , Goldsweig, Andrew M. , Hagler, Donald J. , Hawkins, Beau M., Hijazi, Ziyad M. , Jayasuriya, Sasanka, Klein, Andrew , Kliger, Chad , Mahmud, Ehtisham , Messenger, John C. , Parikh, Sahil A. , Shishehbor, Mehdi H. , Yakubov, Steven J. , Alvarez‐Breckenridge, Jennifer, Baird, Colleen, Baker, David, Berry, Charles H., Bhattacharya, Manisha, Bilazarian, Seth, Bowen, Rosanne, Brounstein, Kevin, Cameron, Cole, Culbertson, Casey , Díaz, P, Emanuele, Susan, Evans, Erin, Fletcher, Rob, Fortune, Tina, Gaiha, Priya, Govender, Devi, Gutfinger, Dan , Haggstrom, Kurt, Herzog, Andrea, Hite, Denise, Kalich, Bethany , Kirkland, Ann, Kohler, Toni, Laurisden, Holly, Livolsi, Kevin, Lombardi, Lois, Marhenke, Kevin, Meikle, Joie, Moat, Neil, Popma, J.J., Rangwala, Novena , Simonton, Chuck, Stokes, J. W., Taber, Margaret , Tieché, Christopher, Venditto, John, Zinn, Laurie, Dangas, George , Daggubati, Ramesh , Shah, Binita , Ang, Lawrence , Cohen, Mauricio G , Goldsweig, Andrew M , Hagler, Donald J , Morray, Brian H , Parikh, Sahil A , Shishehbor, Mehdi H , Szerlip, Molly , Yakubov, Steven J , Grines, Cindy L , Baron, Suzanne J , Rao, Sunil V. , Shah, Binita , Aronow, Herbert D. , Banerjee, Subhash , Justino, Henri , Li, Jun , Morray, Brian H. , Parikh, Sahil A. , Reilly, John P. , Secemsky, Eric A. , Grines, Cindy L. , Baker, David, Berry, Charles, Cavalcante, Rafael , Diaz, Pedro, Kohler, Toni, Lowe, Sarah, Mueller, Megan, Patarca, Roberto , Stokes, Jerry, West, Nick E.J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 16, 2021 | Volume: 98 | Issue: 5 | Pages: 904-913

10.1002/ccd.29898 | PMID 34398509 Get It

AbstractThe Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high‐level field‐wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Evaluating Markers of Immune Tolerance and Angiogenesis in Maternal Blood for an Association with Risk of Pregnancy Loss
Wyatt, Michelle A. , Baumgarten, Sarah C., Weaver, Amy L. , Oort, Chelsie C. Van, Fedyshyn, Bohdana , Ruano, Rodrigo , Shenoy, Chandra C. , Enninga, Elizabeth Ann L. , Van Oort, Chelsie C, Ruano, Rodrigo , Enninga, Elizabeth Ann L

Mayo Clinic

Journal of Clinical Medicine | August 15, 2021 | Volume: 10 | Issue: 16 | Pages: 3579

10.3390/jcm10163579 | PMID 34441875 Get It

Pregnancy loss affects approximately 20% of couples. The lack of a clear cause complicates half of all miscarriages. Early evidence indicates the maternal immune system and angiogenesis regulation are both key players in implantation success or failure. Therefore, this prospective study recruited women in the first trimester with known viable intrauterine pregnancy and measured blood levels of immune tolerance proteins galectin-9 (Gal-9) and interleukin (IL)-4, and angiogenesis proteins (vascular endothelial growth factors (VEGF) A, C, and D) between 5 and 9 weeks gestation. Plasma concentrations were compared between groups defined based on (a) pregnancy outcome and (b) maternal history of miscarriage, respectively. In total, 56 women were recruited with 10 experiencing a miscarriage or pregnancy loss in the 2nd or 3rd trimester and 11 having a maternal history or miscarriage. VEGF-C was significantly lower among women with a miscarriage or pregnancy loss. Gal-9 and VEGF-A concentrations were decreased in women with a prior miscarriage. Identification of early changes in maternal immune and angiogenic factors during pregnancy may be a tool to improve patient counseling on pregnancy loss risk and future interventions to reduce miscarriage in a subset of women.
A systems‐level analysis highlights microglial activation as a modifying factor in common epilepsies
Altmann, André , Ryten, Mina , Nunzio, Martina Di , Ravizza, Teresa , Reynolds, Regina H. , Somani, Alyma, Bacigaluppi, Marco , Iori, Valentina , Sapia, Rossella Di , Cerovic, Milica , Palma, Eleonora , Ruffolo, Gabriele , Botía, Juan A. , Absil, Julie , Alhusaini, Saud , Alvim, Marina K. M. , Auvinen, Pia, Bartolini, Emanuele , Bender, Benjamin , Bergo, Felipe P. G. , Bernardes, Tauana, Bernasconi, Andrea , Bernasconi, Neda , Bernhardt, Boris C. , Blackmon, Karen , Braga, Bárbara , Caligiuri, Maria Eugenia , Calvo, Anna, Carr, Sarah J. A. , Cavalleri, Gianpiero L. , Chen, Jian , Chen, Shuai , Cherubini, Andrea , Concha, Luis , David, Philippe, Delanty, Norman, Depondt, Chantal, Doherty, Colin P. , Domín, Martin , Foley, Sonya , França, Wendy, Gambardella, Antonio , Guerrini, Renzo , Hamandi, Khalid , Hibar, Derrek P., Isaev, Dmitry , Jahanshad, Neda , Kälviäinen, Reetta , Keller, Simon S. , Kotikalapudi, Raviteja , Kwan, Patrick , Langner, Sönke , Lenge, Matteo , Martin, Pascal , Meletti, Stefano , Morita‐Sherman, Marcia , Pariente, José C. , Richardson, Mark P. , Rummel, Christian , Saavalainen, Taavi, Semmelroch, Mira , Striano, Pasquale, Thesen, Thomas , Thomas, Rhys H. , Tondelli, Manuela , Vaudano, Anna Elisabetta , Vivash, Lucy , Podewils, Felix von , Wagner, Jan , Weber, Bernd , Wiest, Roland , Yasuda, Clarissa Lin , Zhang, Junsong , Group, ENIGMA‐Epilepsy Working, Leu, Costin , Avberšek, Andreja , Whelan, Christopher D. , Thompson, Paul M. , McDonald, Carrie R. , Di Sapia, Rossella , Bender, Benjamin , Severino, Mariasavina , Thom, Maria , Yasuda, Clarissa L , Doherty, Colin P , Cavalleri, Gianpiero L , Weber, Bernd , Thompson, Paul M , Richardson, Mark P , Guerrini, Renzo , Thomas, Rhys H , Leu, Costin , Tolomeo, Daniele , Micotti, Edoardo , Bargalló, Núria , Carlson, Chad , Cendes, Fernando , Devinsky, Orrin , Focke, Niels K. , Jackson, Graeme D. , Kochunov, Peter V , Kowalczyk, Magdalena A. , Kuzniecky, Ruben , Labate, Angelo , Liu, Min , Mascalchi, Mario , Morita, Márcia Elisabete , O’Brien, Terence J. , Rodríguez‐Cruces, Raúl , Tortora, Domenico , Zhang, Guohao , Group, ENIGMA‐Epilepsy Working, Vezzani, Annamaria , Sisodiya, Sanjay

Mayo Clinic

Neuropathology and Applied Neurobiology | August 13, 2021 | Volume: 48 | Issue: 1 | Pages: No page available

10.1111/nan.12758 | PMID 34388852 Get It

Abstract Aims The causes of distinct patterns of reduced cortical thickness in the common human epilepsies, detectable on neuroimaging and with important clinical consequences, are unknown. We investigated the underlying mechanisms of cortical thinning using a systems‐level analysis. Methods Imaging‐based cortical structural maps from a large‐scale epilepsy neuroimaging study were overlaid with highly spatially resolved human brain gene expression data from the Allen Human Brain Atlas. Cell‐type deconvolution, differential expression analysis and cell‐type enrichment analyses were used to identify differences in cell‐type distribution. These differences were followed up in post‐mortem brain tissue from humans with epilepsy using Iba1 immunolabelling. Furthermore, to investigate a causal effect in cortical thinning, cell‐type‐specific depletion was used in a murine model of acquired epilepsy. Results We identified elevated fractions of microglia and endothelial cells in regions of reduced cortical thickness. Differentially expressed genes showed enrichment for microglial markers and, in particular, activated microglial states. Analysis of post‐mortem brain tissue from humans with epilepsy confirmed excess activated microglia. In the murine model, transient depletion of activated microglia during the early phase of the disease development prevented cortical thinning and neuronal cell loss in the temporal cortex. Although the development of chronic seizures was unaffected, the epileptic mice with early depletion of activated microglia did not develop deficits in a non‐spatial memory test seen in epileptic mice not depleted of microglia. Conclusions These convergent data strongly implicate activated microglia in cortical thinning, representing a new dimension for concern and disease modification in the epilepsies, potentially distinct from seizure control.
What men want: Results from a national survey on decision making for prostate cancer treatment and research participation
Osian, Sarah M. Rausch, Bryant, Curtis M., Morris, Christopher G. , Mendenhall, Nancy P. , Hoppe, Bradford S.

Mayo Clinic

Clinical and Translational Science | August 11, 2021 | Volume: 14 | Issue: 6 | Pages: 2314-2326

10.1111/cts.13090 | PMID 34379363 Get It

AbstractData comparing outcomes in prostate cancer and factors affecting treatment choice are sparse. To inform the design of a comparative effectiveness clinical trial, we engaged patients in developing a 28‐question survey about decision making on treatment and research participation and dispersed it among men greater than or equal to 50 years of age. The 1046 respondents ranked long‐term clinical outcomes as most important in making treatment decisions, specific functional outcomes as slightly less important, and duration, location, and cost of treatment as least important. Treatment choice was strongly impacted by side effect profile. Responses to whether the subject would agree to participation in a randomized trial between two types of radiation with minimal differences in outcomes were “yes” in 15%, “no” in 39%, and “undecided” in 46%. Responses to whether the subject would agree to participation in a randomized trial between two treatment durations with similar outcomes were yes in 36%, no in 24%, and undecided in 40%. Findings suggest many potential patients have strong treatment preferences and are averse to randomization, particularly when outcomes of importance may be affected. Patient engagement in study design and novel nonrandomized trial designs may offer a path to increase clinical trial success.
Neoadjuvant Study of Niraparib in Patients With HER2-Negative, BRCA-Mutated Resectable Breast Cancer
Liu, Minetta C. , Irie, Hanna Y. , Santa‐Maria, Cesar A. , Reeves, James E., Pan, Peng , Shan, Ming , Tang, Yongqiang , Graham, Julie , Hazard, Sebastien , Isakoff, Steven J. , Spring, Laura , Han, Hyo S , Hamilton, Erika , Santa-Maria, Cesar Augusto , Pan, Peng, Graham, Julie, Ellisen, Leif W.

Mayo Clinic

No container title available | August 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-711810/v1 Get It

Abstract This study evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6/15) of patients who only received niraparib (2–6 cycles) had pathological complete response. No new safety signals were identified and high niraparib intratumoral concentration was observed.
Development of the National Otolaryngology Interest Group: Conception to Implementation
Farsar, Cameron J., Sperling, Jared A., Quesada, P , Solis, Roberto N. , Ojeaga, Macaulay , Carlson, Matthew L. , Sperling, Jared, Bowe, Sarah N. , Brown, Jason R. , Levi, Jessica R.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 3, 2021 | Volume: 166 | Issue: 3 | Pages: 413-416

10.1177/01945998211033237 | PMID 34340617 Get It

Otolaryngology is a small and highly sought‐after surgical subspecialty with sparse residency positions, making it competitive to match into. Allopathic (MD) students without home otolaryngology residency programs, osteopathic (DO) medical students, and underrepresented minorities have historically faced additional challenges in matching into otolaryngology. These specific populations generally experience limited opportunities in establishing mentors, engaging in scholarly activity, and gaining early exposure to clinical settings. Even though the American Osteopathic Association and the Accreditation Council for Graduate Medical Education merger was in part established to create equity among applicants, there remains a substantial disparity among the match rates of medical students of various educational and cultural backgrounds. The National Otolaryngology Interest Group is a student‐led interest group created to provide all medical students, especially those facing barriers, with the resources needed to best prepare for matching into an otolaryngology residency program and ultimately a career in otolaryngology.
Mental Health and Chemical Dependency Services at US Cancer Centers
Niazi, Shehzad K. , Spaulding, Aaron , Meier, Sarah , Cornell, Lauren , Clark, Matthew M. , Rummans, Teresa A. , Meier, Sarah K, Crook, Julia E. , Spaulding, Aaron , Brennan, Emily , Cornell, Lauren F , Ailawadhi, Sikander

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 829-838

10.6004/jnccn.2020.7657 | PMID 33662936 Get It

Background: It is standard of care and an accreditation requirement to screen for and address distress and psychosocial needs in patients with cancer. This study assessed the availability of mental health (MH) and chemical dependency (CD) services at US cancer centers. Methods: The 2017–2018 American Hospital Association (AHA) survey, Area Health Resource File, and Centers for Medicare & Medicaid Services Hospital Compare databases were used to assess availability of services and associations with hospital-level and health services area (HSA)–level characteristics. Results: Of 1,144 cancer centers surveyed, 85.4% offered MH services and 45.5% offered CD services; only 44.1% provided both. Factors associated with increased adjusted odds of offering MH services were teaching status (odds ratio [OR], 1.76; 95% CI, 1.18–2.62), being a member of a hospital system (OR, 2.00; 95% CI, 1.31–3.07), and having more beds (OR, 1.04 per 10-bed increase; 95% CI, 1.02–1.05). Higher population estimate (OR, 0.98; 95% CI, 0.97–0.99), higher percentage uninsured (OR, 0.90; 95% CI, 0.86–0.95), and higher Mental Health Professional Shortage Area level in the HSA (OR, 0.99; 95% CI, 0.98–1.00) were associated with decreased odds of offering MH services. Government-run (OR, 2.85; 95% CI, 1.30–6.22) and nonprofit centers (OR, 3.48; 95% CI, 1.78–6.79) showed increased odds of offering CD services compared with for-profit centers. Those that were members of hospital systems (OR, 1.61; 95% CI, 1.14–2.29) and had more beds (OR, 1.02; 95% CI, 1.01–1.03) also showed increased odds of offering these services. A higher percentage of uninsured patients in the HSA (OR, 0.92; 95% CI, 0.88–0.97) was associated with decreased odds of offering CD services. Conclusions: Patients’ ability to pay, membership in a hospital system, and organization size may be drivers of decisions to co-locate services within cancer centers. Larger organizations may be better able to financially support offering these services despite poor reimbursement rates. Innovations in specialty payment models highlight opportunities to drive transformation in delivering MH and CD services for high-need patients with cancer.
The extravascular implantable cardioverter‐defibrillator: The pivotal study plan
Crozier, Ian , O’Donnell, David , Boersma, Lucas V.A. , Murgatroyd, Francis , Manlucu, Jaimie , Knight, Bradley P. , Birgersdotter‐Green, Ulrika , Leclercq, Christophe , Thompson, Amy , Sawchuk, Robert, Willey, Sarah, Wiggenhorn, Christopher, Friedman, Paul A. , Friedman, Paul A , Knight, Bradley P , Boersma, Lucas , Crozier, Ian

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 29, 2021 | Volume: 32 | Issue: 9 | Pages: 2371-2378

10.1111/jce.15190 | PMID 34322918 Get It

AbstractBackgroundTransvenous implantable cardioverter defibrillators (TV ICD) provide life‐saving therapy for millions of patients worldwide. However, they are susceptible to several potential short‐ and long‐ term complications including cardiac perforation and pneumothorax, lead dislodgement, venous obstruction, and infection. The extravascular ICD system's novel design and substernal implant approach avoids the risks associated with TV ICDs while still providing pacing features and similar generator size to TV ICDs.Study DesignThe EV ICD pivotal study is a prospective, multicenter, single‐arm, nonrandomized, premarket clinical study designed to examine the safety and acute efficacy of the system. This study will enroll up to 400 patients with a Class I or IIa indication for implantation of an ICD. Implanted subjects will be followed up to approximately 3.5 years, depending on when the patient is enrolled.ObjectiveThe clinical trial is designed to demonstrate safety and effectiveness of the EV ICD system in human use. The safety endpoint is freedom from major complications, while the efficacy endpoint is defibrillation success. Both endpoints will be assessed against prespecified criteria. Additionally, this study will evaluate antitachycardia pacing performance, electrical performance, extracardiac pacing sensation, asystole pacing, appropriate and inappropriate shocks, as well as a summary of adverse events.ConclusionThe EV ICD pivotal study is designed to provide clear evidence addressing the safety and efficacy performance of the EV ICD System.